TY - CHAP
T1 - Conventional vs controlled-release CBZ
T2 - A multicentre, double-blind, cross-over study
AU - Canger, R.
AU - Belvedere, D.
AU - Canevini, M. P.
AU - Monza, G. C.
AU - Monaco, F.
AU - Sechi, G. P.
AU - Mutani, R.
AU - Gianelli, M.
AU - Pisani, F.
AU - Oteri, G.
AU - Romano, F.
AU - Zaccara, G.
AU - Muscas, G. C.
AU - Zagnoni, P.
AU - Seliak, D.
AU - Perla, F.
AU - Altamura, A. C.
AU - Panetta, B.
AU - Girardi, T.
PY - 1988
Y1 - 1988
N2 - Efficacy of tolerability of a new controlled-release (CR) formulation of carbamazepine (CBZ) (Tegretol CR), were assessed in a formal multicentre, double-blind, cross-over trial, carried out in 48 epileptic patients (21 men, 27 women; mean age 34 years). Before entering the study, patietns (pts) had been taking conventional CBZ monotherapy, but without a complete seizure control (n = 22 pts), or with intermittent side-effects (n = 4 pts), or with seizures and intermittent side-effects (n = 22 pts). Eligible pts were given conventional CBZ and CR CBZ, in randomized sequence, at individualized daily doses, subdivided in the lowest number of administration. Each period of the cross-over consisted of a first phase of titration (lasting up to 2 months) and of a second phase of maintenance (lasting 1 month) used for evaluation. A 12-hour plasma CBZ and CBZ-epoxide profile concentrations, as well as efficacy and tolerability, were evaluated at the end of each period. The mean daily CBZ dose has been increased by 15% during administration of the CR formulation. Fluctuation indices of total CBZ and 10,11-epoxide plasma levels at steady-state were significantly (p <0.02) lower during CR CBZ treatment, leading to a significant (p <0.001) decrease of intermittent side-effects (6 pts on CR CBZ vs 36 on conventional CBZ). In addition, a complete seizure control was obtained in 4 pts when treated with CR CBZ; 38 pts on CR CBZ (vs 15 pts on conventional CBZ) were treated with a b.i.d. regimen.
AB - Efficacy of tolerability of a new controlled-release (CR) formulation of carbamazepine (CBZ) (Tegretol CR), were assessed in a formal multicentre, double-blind, cross-over trial, carried out in 48 epileptic patients (21 men, 27 women; mean age 34 years). Before entering the study, patietns (pts) had been taking conventional CBZ monotherapy, but without a complete seizure control (n = 22 pts), or with intermittent side-effects (n = 4 pts), or with seizures and intermittent side-effects (n = 22 pts). Eligible pts were given conventional CBZ and CR CBZ, in randomized sequence, at individualized daily doses, subdivided in the lowest number of administration. Each period of the cross-over consisted of a first phase of titration (lasting up to 2 months) and of a second phase of maintenance (lasting 1 month) used for evaluation. A 12-hour plasma CBZ and CBZ-epoxide profile concentrations, as well as efficacy and tolerability, were evaluated at the end of each period. The mean daily CBZ dose has been increased by 15% during administration of the CR formulation. Fluctuation indices of total CBZ and 10,11-epoxide plasma levels at steady-state were significantly (p <0.02) lower during CR CBZ treatment, leading to a significant (p <0.001) decrease of intermittent side-effects (6 pts on CR CBZ vs 36 on conventional CBZ). In addition, a complete seizure control was obtained in 4 pts when treated with CR CBZ; 38 pts on CR CBZ (vs 15 pts on conventional CBZ) were treated with a b.i.d. regimen.
UR - http://www.scopus.com/inward/record.url?scp=0024262839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024262839&partnerID=8YFLogxK
M3 - Chapter
AN - SCOPUS:0024262839
SP - 419
EP - 421
BT - Bollettino - Lega Italiana contro l'Epilessia
ER -